SynAct Pharma (SYNACT) Aktiedagarna 2026 summary

Strategic focus and therapeutic approach

• Shifted focus to developing pro-resolution therapies for immune system diseases, targeting both chronic and acute inflammatory conditions.

• Pro-resolution immunology aims to modulate immune cells without immunosuppression, potentially reducing side effects compared to current treatments.

• Lead compound, resomelagon (AP1189), is a once-daily oral therapy with a novel, non-immunosuppressive mechanism.

Clinical development and pipeline

• Lead program is in phase II-B for rheumatoid arthritis, with top-line data expected in June.

• Pipeline includes additional trials in respiratory viral infections and dengue, leveraging the broad applicability of the mechanism.

• Animal models and ongoing clinical programs support potential efficacy across multiple indications.

Market opportunity and positioning

• Addressing a large market, with rheumatoid arthritis and related indications representing a $26–30 billion opportunity.

• Targeting patients who do not respond to first-line therapies, aiming to delay or avoid progression to expensive biologics.

• Non-immunosuppressive profile could allow earlier intervention and improved safety.